Biolegend, 110737, Brilliant Violet 605™ anti-mouse CD45.1 Antibody, 125microl

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: SJL mouse thymocytes and splenocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, in vitro blocking of B cell responses1,2, immunohistochemical staining of frozen sections: OCT embedded7 and acetone-fixed4-6 (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).
Application References(PubMed link indicates BioLegend citation): Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block) Yakura H, et al. 1986. J. Immunol. 136:2729. (Block) Shen FW, et al. 1986. Immunogenetics 24:146. (IP) Suzuki K, et al. 2000. Immunity 13:691. (IHC-F) Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC-F) Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC-F) Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC-F) Pascal V, et al. 2007. J. Immunol. 179:1751. (FC) Mende I, et al. 2006. Blood 107:1383. (IHC-F, FC) Phan TG, et al. 2007. Nature Immunol. 8:992. (FC) Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed Pascal V, et al.2007. J. Immunol. 179:1751. PubMed Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed Li LX, et al. 2010. J. Immunol. 184:1728. PubMed Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations: Kuczynski EA, et al. 2022. EMBO Mol Med. 14:e15816. PubMed Hu Q, et al. 2022. Cell Rep. 40:111035. PubMed Roy IM, et al. 2022. iScience. 25:105171. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Krummey SM, et al. 2020. Cell Reports. 30(5):1282-1291.e5.. PubMed Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Lu SX, et al. 2021. Cell. . PubMed Sugimoto C, et al. 2022. Elife. 11:. PubMed Wang H, et al. 2022. Curr Protoc. 2:e446. PubMed Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed Lam WY et al. 2018. Cell reports. 24(9):2479-2492 . PubMed Wagner JA, et al. 2020. Cell Rep. 31:107720. PubMed Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed Duan L, et al. 2021. Immunity. 54:2256. PubMed He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed Glaros V, et al. 2021. Immunity. 54:2005. PubMed Mansell E, et al. 2020. Cell Stem Cell. . PubMed Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Crauste F, et al. 2017. Cell Syst. 0.379166667. PubMed Engblom C, et al. 2017. Science. 358:6367. PubMed Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed Celik H, et al. 2018. Cancer Cell. 34:741. PubMed Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed Pai CS, et al. 2020. Immunity. 50(2):477-492. PubMed Bosteels C, et al. 2020. Immunity. 52(6):1039-1056.e9.. PubMed Rivera CA, et al. 2022. Immunity. 55:129. PubMed Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
RRID: AB_11204076 (BioLegend Cat. No. 110737) AB_2562565 (BioLegend Cat. No. 110738)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45.1 on UniProt.org
Clone: A20
Regulatory Status: RUO
Other Names: T200, Ly-5.1, LCA
Isotype: Mouse (A.SW) IgG2a, κ